Showing results (601-610 of 727) with videos related to
Sort By:
Pageof 73
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 1, 2019
Efficacy of Platinum/Pemetrexed Combination Chemotherapy in ALK-Positive NSCLC Refractory to Second-Generation ALK InhibitorsJessica J Lin, Adam J Schoenfeld, Viola W Zhu, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 4, 2023
Efficacy of Lorlatinib in Treatment-Naive Patients With ALK-Positive Advanced NSCLC in Relation to EML4::ALK Variant Type and ALK With or Without TP53 MutationsAlessandra Bearz, Jean-François Martini, Jacek Jassem, et al.Lung Cancer (Amsterdam, Netherlands)|December 10, 2021
Genetic landscape of patients with ALK-rearranged non-small-cell lung cancer (NSCLC) and response to ceritinib in ASCEND-1 studyD S-W Tan, M Thomas, D-W Kim, et al.The Journal of Physical Chemistry. B|July 10, 2019
Antioxidant Sensing by Spiropyrans: Substituent Effects and NMR Spectroscopic StudiesJoel Garcia, J Bennett Addison, Stephen Z Liu, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 11, 2012
A phase I study of erlotinib and hydroxychloroquine in advanced non-small-cell lung cancerSarah B Goldberg, Jeffrey G Supko, Joel W Neal, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 19, 2020
Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX studyT Mok, D R Camidge, S M Gadgeel, et al.Proceedings of the National Academy of Sciences of the United States of America|January 22, 2015
Improved tumor vascularization after anti-VEGF therapy with carboplatin and nab-paclitaxel associates with survival in lung cancerRebecca S Heist, Dan G Duda, Dushyant V Sahani, et al.The Journal of Organic Chemistry|January 27, 2016
Toward Structural Correctness: Aquatolide and the Importance of 1D Proton NMR FID ArchivingGuido F Pauli, Matthias Niemitz, Jonathan Bisson, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 9, 2023
Early Circulating Tumor DNA Dynamics and Efficacy of Lorlatinib in Patients With Treatment-Naive, Advanced, ALK-Positive NSCLCRoss A Soo, Jean-François Martini, Anthonie J van der Wekken, et al.The New England Journal of Medicine|June 7, 2017
Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung CancerSolange Peters, D Ross Camidge, Alice T Shaw, et al.Pageof 73